FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2549271193> ?p ?o ?g. }

• W2549271193 endingPage "268" @default.
• W2549271193 startingPage "262" @default.
• W2549271193 abstract "Comprehensive recommendations for maintenance therapy after autologous stem cell transplantation (ASCT) for patients with multiple myeloma (MM) have yet to be defined. Bortezomib has been utilized as maintenance therapy after ASCT, but data attesting to the safety and efficacy of this agent compared with lenalidomide in the post-ASCT setting are limited. Therefore, we retrospectively analyzed the outcomes of 102 patients with MM who received maintenance therapy with bortezomib after ASCT at Duke University's adult bone marrow transplant clinic between 2005 and 2015. Maintenance with bortezomib was initiated between 60 and 90 days after ASCT as a single agent 1.3 mg/m2 once every 2 weeks (n = 92) or in combination with lenalidomide (10 mg/day) (n = 10). The median age at ASCT was 64 (range, 31 to 78). Of the 99 patients with molecular data available, 42% had high-risk cytogenetics (including d17p, t(4;14), +1q, and t(14;16) by fluorescein in situ hybridization). Overall, 46% of patients experienced side effects from maintenance therapy, with 31% of all patients experiencing peripheral neuropathy. In total, 2% of patients required discontinuation of bortezomib maintenance because of adverse events. No secondary malignancies were reported from the therapy. The median progression-free survival (PFS) for patients receiving maintenance therapy with bortezomib after ASCT was 36.5 months (95% confidence interval [CI], 21.3 to not available) and median overall survival was 72.7 months (95% CI, 63.9 to not available). The PFS of patients with high-risk cytogenetics was not statistically significantly different from those with standard-risk cytogenetics, suggesting that maintenance with bortezomib may help overcome the impact of high-risk cytogenetics on early progression. These results indicate that maintenance therapy with bortezomib represents a safe, well-tolerated, and efficacious option for patients with high-risk cytogenetics, renal insufficiency, an inability to tolerate lenalidomide, or a previous history of another cancer." @default.
• W2549271193 created "2016-11-30" @default.
• W2549271193 creator A5008453908 @default.
• W2549271193 creator A5012017882 @default.
• W2549271193 creator A5018922885 @default.
• W2549271193 creator A5027756167 @default.
• W2549271193 creator A5033550793 @default.
• W2549271193 creator A5034651124 @default.
• W2549271193 creator A5037247107 @default.
• W2549271193 creator A5049930588 @default.
• W2549271193 creator A5051395684 @default.
• W2549271193 creator A5061865992 @default.
• W2549271193 creator A5063907259 @default.
• W2549271193 creator A5073746929 @default.
• W2549271193 creator A5077581687 @default.
• W2549271193 date "2017-02-01" @default.
• W2549271193 modified "2023-09-26" @default.
• W2549271193 title "Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma" @default.
• W2549271193 cites W1974656498 @default.
• W2549271193 cites W1988265934 @default.
• W2549271193 cites W2026448323 @default.
• W2549271193 cites W2039496823 @default.
• W2549271193 cites W2043759160 @default.
• W2549271193 cites W2057998903 @default.
• W2549271193 cites W2060588247 @default.
• W2549271193 cites W2091346949 @default.
• W2549271193 cites W2093757149 @default.
• W2549271193 cites W2099395323 @default.
• W2549271193 cites W2102591890 @default.
• W2549271193 cites W2104238785 @default.
• W2549271193 cites W2104993929 @default.
• W2549271193 cites W2108601475 @default.
• W2549271193 cites W2109013784 @default.
• W2549271193 cites W2125721471 @default.
• W2549271193 cites W2128084036 @default.
• W2549271193 cites W2142368474 @default.
• W2549271193 cites W2143425592 @default.
• W2549271193 cites W2144728882 @default.
• W2549271193 cites W2151989390 @default.
• W2549271193 cites W2167310611 @default.
• W2549271193 cites W2169151446 @default.
• W2549271193 cites W2169210165 @default.
• W2549271193 cites W2235535864 @default.
• W2549271193 cites W2286843233 @default.
• W2549271193 cites W2556510606 @default.
• W2549271193 cites W2557969576 @default.
• W2549271193 cites W2979424907 @default.
• W2549271193 cites W4235854784 @default.
• W2549271193 doi "https://doi.org/10.1016/j.bbmt.2016.11.010" @default.
• W2549271193 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27856369" @default.
• W2549271193 hasPublicationYear "2017" @default.
• W2549271193 type Work @default.
• W2549271193 sameAs 2549271193 @default.
• W2549271193 citedByCount "31" @default.
• W2549271193 countsByYear W25492711932017 @default.
• W2549271193 countsByYear W25492711932018 @default.
• W2549271193 countsByYear W25492711932019 @default.
• W2549271193 countsByYear W25492711932020 @default.
• W2549271193 countsByYear W25492711932021 @default.
• W2549271193 countsByYear W25492711932022 @default.
• W2549271193 countsByYear W25492711932023 @default.
• W2549271193 crossrefType "journal-article" @default.
• W2549271193 hasAuthorship W2549271193A5008453908 @default.
• W2549271193 hasAuthorship W2549271193A5012017882 @default.
• W2549271193 hasAuthorship W2549271193A5018922885 @default.
• W2549271193 hasAuthorship W2549271193A5027756167 @default.
• W2549271193 hasAuthorship W2549271193A5033550793 @default.
• W2549271193 hasAuthorship W2549271193A5034651124 @default.
• W2549271193 hasAuthorship W2549271193A5037247107 @default.
• W2549271193 hasAuthorship W2549271193A5049930588 @default.
• W2549271193 hasAuthorship W2549271193A5051395684 @default.
• W2549271193 hasAuthorship W2549271193A5061865992 @default.
• W2549271193 hasAuthorship W2549271193A5063907259 @default.
• W2549271193 hasAuthorship W2549271193A5073746929 @default.
• W2549271193 hasAuthorship W2549271193A5077581687 @default.
• W2549271193 hasBestOaLocation W25492711931 @default.
• W2549271193 hasConcept C126322002 @default.
• W2549271193 hasConcept C141071460 @default.
• W2549271193 hasConcept C143998085 @default.
• W2549271193 hasConcept C2776063141 @default.
• W2549271193 hasConcept C2776364478 @default.
• W2549271193 hasConcept C2776694085 @default.
• W2549271193 hasConcept C2777478702 @default.
• W2549271193 hasConcept C2778283404 @default.
• W2549271193 hasConcept C2778715236 @default.
• W2549271193 hasConcept C2779050716 @default.
• W2549271193 hasConcept C2911091166 @default.
• W2549271193 hasConcept C71924100 @default.
• W2549271193 hasConceptScore W2549271193C126322002 @default.
• W2549271193 hasConceptScore W2549271193C141071460 @default.
• W2549271193 hasConceptScore W2549271193C143998085 @default.
• W2549271193 hasConceptScore W2549271193C2776063141 @default.
• W2549271193 hasConceptScore W2549271193C2776364478 @default.
• W2549271193 hasConceptScore W2549271193C2776694085 @default.
• W2549271193 hasConceptScore W2549271193C2777478702 @default.
• W2549271193 hasConceptScore W2549271193C2778283404 @default.
• W2549271193 hasConceptScore W2549271193C2778715236 @default.
• W2549271193 hasConceptScore W2549271193C2779050716 @default.

• next